Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients

Journal of Infectious Diseases

Volumn 202, Issue 4, 2010, Pages 585-594

  Abate, Davide ^a   Saldan, Alda ^a   Fiscon, Marta ^a   Cofano, Simona ^a   Paciolla, Adriana ^a   Furian, Lucrezia ^a   Ekser, Burcin ^a   Biasolo, Maria Angela ^a   Cusinato, Riccardo ^a   Mengoli, Carlo ^a   Bonfante, Luciana ^a   Rossi, Barbara ^a   Rigotti, Paolo ^a   Sgarabotto, Dino ^a   Barzon, Luisa ^a   Palù, Giorgio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; GAMMA INTERFERON; GENZYME; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CELLULAR IMMUNITY; CROSS-SECTIONAL STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY DONOR; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; AGED; ANTILYMPHOCYTE SERUM; ANTIVIRAL AGENTS; CHEMOPREVENTION; CROSS-SECTIONAL STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INTERFERON-GAMMA; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; T-LYMPHOCYTES; TRANSPLANTATION; VIREMIA;

EID: 77954736362     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/654931     Document Type: Article

References (27)

1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601-2614.
2. Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation-challenging the status quo. Clin Transplant 2007; 21:149-158.
3. Fishman JA. Infection in renal transplant recipients. Semin Nephrol 2007; 27:445-461.
4. Pass RF. Cytomegalovirus. In: Knipe D, Howley P, eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2001:2675-2705.
5. Mocarski ES Jr, Courcelle CT. Cytomegaloviruses and their replication. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2001:2629-2673.
6. Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003; 10:60-65.
7. Gerna G, Lilleri D. Monitoring transplant patients for human cytomegalovirus: diagnostic update. Herpes 2006; 13:4-11.
8. Griffiths P, Whitley R, Snydman DR, Singh N, Boeckh M. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007. Herpes 2008; 15:4-12.
9. Humar A, Fishman JA. Donor-derived infection: old problem, new solutions? Am J Transplant 2008; 8:1087-1088.
10. Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49:873-883.
11. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 2008; 8:2111-2118.
12. Tu W, Potena L, Stepick-Biek P, et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation 2006; 114:1608-1615.
13. Maecker HT, Maino VC, Picker LJ. Immunofluorescence analysis of Tcell responses in health and disease. J Clin Immunol 2000; 20:391-399.
14. Maecker HT, Maino VC. Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry. Hum Immunol 2004; 65:493-499.
15. Cummins NW, Deziel PJ, Abraham RS, Razonable RR. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation. Transpl Infect Dis 2009; 11:20-27.
16. Gerna G, Lilleri D, Fornara C, et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006; 6:2356-2364.
17. Egli A, Binet I, Binggeli S, et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008; 6:29.
18. Baldanti F, Lilleri D, Gerna G. Monitoring human cytomegalovirus infection in transplant recipients. J Clin Virol 2008; 41:237-241.
19. Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 2005; 62:S7-S13.
20. Legendre C, Pascual M. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences. Clin Infect Dis 2008; 46:732-740.
21. Mengoli C, Cusinato R, Biasolo MA, Cesaro S, Parolin C, Palu G. Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection. J Med Virol 2004; 74:78-84.
22. Strippoli GF, Hodson EM, Jones C, Craig JC. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006; 81:139-145.
23. Hodson EM, Craig JC, Strippoli GF,Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008; (2):CD003774.
24. Lilleri D, Lazzarotto T, Ghisetti V, et al. Multicenter quality control study for human cytomegalovirus DNAemia quantification. New Microbiol 2009; 32:245-253.
25. Haririan A, Morawski K, West MS, et al. Sirolimus exposure during the early post-transplant period reduces the risk ofCMVinfection relative to tacrolimus in renal allograft recipients. Clin Transplant 2007; 21:466-471.
26. Demopoulos L, Polinsky M, Steele G, et al. Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc 2008; 40: 1407-1410.
27. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21:1387-1394.